SCHEMBL16620023

SCHEMBL16620023

O=C(Nc1ccc(CBr)c(F)c1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
EPHX2 P34913 2/20 0.44
NR1H4 Q96RI1 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
NPY5R Q15761 4/20 0.42
MAPT P10636 1/20 0.41
MTNR1B P49286 1/20 0.41
AR P10275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274988 0.83 AR (0.51) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL29999042 0.83 AR (0.51) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL16620122 0.83 EPHX2 (0.57) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL6602968 0.80 CYP1A2 (0.56) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL31146306 0.80 CYP1A2 (0.56) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL29535627 0.79 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL6557195 0.79 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL16620534 0.77 KDM4E (0.48) CYP1A2CYP2C9CYP2C19SMN1; SMN2GAA
SCHEMBL24474072 0.76 KMT2A (0.56) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2
SCHEMBL29486454 0.76 AR (0.56) CYP1A2CYP2C9CYP2C19L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015049325-A1 THERAPEUTIC INHIBITORS OF CDK8 AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2015-04-09 WO disclosed
US-20150045255-A1 Endometrial Phase or Endometrial Cancer Biomarkers WALFISH, PAUL (CA) 2015-02-12 US disclosed